Panacos surges on HIV response data

Shares of Panacos shot up yesterday when the drug developer reported that it discovered factors that predict response to bevirimat, its lead HIV maturation inhibitor. Patients who had few mutations on the HIV Gag protein were more likely to respond to bevirimat. When researchers analyzed data from a recent Phase II trial, they found that about 50 percent of the 100 patients studied have these specific changes in Gag. "In a very short period of time we have made a number of significant discoveries with regard to bevirimat. We can specifically target the patients who will respond well to bevirimat in advance. In that population, we have seen a dramatic treatment response," noted Alan W. Dunton, Panacos' President and CEO. Simple genotype test will help determine which patients benefit from bevirimat; additional trials will be needed to test the drug in this group.

- see this release
- read the BusinessWeek article for more

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.